BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

...to treat osteoporosis. EffRx Pharmaceuticals S.A. has a formulation of alendronate approved to treat osteoporosis. Merrion Pharmaceuticals plc...
BioCentury | Oct 31, 2011
Company News

Merrion, Novo Nordisk deal

...Novo Nordisk declined to exercise its option under a 2010 deal to license rights to Merrion's...
...Permeation Enhancement Technology (GIPET) absorption-enhancing technology for use with an undisclosed diabetes compound from Novo. Merrion...
...Novo to move forward with the compound. Details were not disclosed (see BioCentury, Jan. 3). Merrion...
BioCentury | May 9, 2011
Clinical News

NN1952: Development discontinued

...of oral NN1952 rapid-acting insulin in its current formulation was significantly influenced by food intake. Merrion...
...technology to develop and commercialize oral formulations of insulin analogs (see BioCentury, Dec. 8, 2008). Merrion Pharmaceuticals plc...
BioCentury | Feb 7, 2011
Clinical News

NN9925: Development discontinued

...uses GIPET technology from Merrion, was in Phase I testing to treat Type II diabetes. Merrion Pharmaceuticals plc...
BioCentury | Jan 3, 2011
Company News

Merrion, Novo Nordisk deal

...The partners will use Merrion Gastrointestinal Permeation Enhancement Technology (GIPET) absorption-enhancing technology in a feasibility study...
...Nordisk, which received a warrant to purchase up to €1.5 million ($2 million) shares of Merrion...
...€2.73, has an option to enter into a further licensing deal to use the technology. Merrion...
BioCentury | Dec 13, 2010
Company News

Merrion deal

...company will then have an option for the GIPET technology. Further terms were not disclosed. Merrion Pharmaceuticals plc...
BioCentury | Dec 6, 2010
Company News

Merrion, Rebel Pharmaceuticals LLC deal

...The companies will use Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) to improve the oral bioavailability and...
...licensing deal, which would include undisclosed milestone and royalty payments. Further terms were not disclosed. Merrion Pharmaceuticals plc...
BioCentury | Oct 25, 2010
Regulation

Haunted by Byetta

...Inc. to make the molecule resistant to enzymatic degradation, while NN9925 uses GIPET technology from Merrion Pharmaceuticals plc...
...NYSE:GSK), London, U.K. Human Genome Sciences Inc. (NASDAQ:HGSI), Rockville, Md. Ipsen Group (Euronext:IPN), Paris, France Merrion Pharmaceuticals plc...
BioCentury | May 24, 2010
Company News

Merrion management update

Merrion Pharmaceuticals plc (ISE:MERR), Dublin, Ireland Business: Drug delivery Hired: Hing Kin Chan as CBO, formerly CBO of DBV Technologies WIR Staff...
BioCentury | Feb 18, 2010
Cover Story

Gut punch to osteoporosis

...findings in that regard are promising and intriguing, said Thomas Leonard, VP and CSO of Merrion Pharmaceuticals plc...
...as dogs or monkeys-because murine models do not metabolize bone the same way humans do. Merrion...
...Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Merrion Pharmaceuticals plc...
Items per page:
1 - 10 of 45
BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

...to treat osteoporosis. EffRx Pharmaceuticals S.A. has a formulation of alendronate approved to treat osteoporosis. Merrion Pharmaceuticals plc...
BioCentury | Oct 31, 2011
Company News

Merrion, Novo Nordisk deal

...Novo Nordisk declined to exercise its option under a 2010 deal to license rights to Merrion's...
...Permeation Enhancement Technology (GIPET) absorption-enhancing technology for use with an undisclosed diabetes compound from Novo. Merrion...
...Novo to move forward with the compound. Details were not disclosed (see BioCentury, Jan. 3). Merrion...
BioCentury | May 9, 2011
Clinical News

NN1952: Development discontinued

...of oral NN1952 rapid-acting insulin in its current formulation was significantly influenced by food intake. Merrion...
...technology to develop and commercialize oral formulations of insulin analogs (see BioCentury, Dec. 8, 2008). Merrion Pharmaceuticals plc...
BioCentury | Feb 7, 2011
Clinical News

NN9925: Development discontinued

...uses GIPET technology from Merrion, was in Phase I testing to treat Type II diabetes. Merrion Pharmaceuticals plc...
BioCentury | Jan 3, 2011
Company News

Merrion, Novo Nordisk deal

...The partners will use Merrion Gastrointestinal Permeation Enhancement Technology (GIPET) absorption-enhancing technology in a feasibility study...
...Nordisk, which received a warrant to purchase up to €1.5 million ($2 million) shares of Merrion...
...€2.73, has an option to enter into a further licensing deal to use the technology. Merrion...
BioCentury | Dec 13, 2010
Company News

Merrion deal

...company will then have an option for the GIPET technology. Further terms were not disclosed. Merrion Pharmaceuticals plc...
BioCentury | Dec 6, 2010
Company News

Merrion, Rebel Pharmaceuticals LLC deal

...The companies will use Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) to improve the oral bioavailability and...
...licensing deal, which would include undisclosed milestone and royalty payments. Further terms were not disclosed. Merrion Pharmaceuticals plc...
BioCentury | Oct 25, 2010
Regulation

Haunted by Byetta

...Inc. to make the molecule resistant to enzymatic degradation, while NN9925 uses GIPET technology from Merrion Pharmaceuticals plc...
...NYSE:GSK), London, U.K. Human Genome Sciences Inc. (NASDAQ:HGSI), Rockville, Md. Ipsen Group (Euronext:IPN), Paris, France Merrion Pharmaceuticals plc...
BioCentury | May 24, 2010
Company News

Merrion management update

Merrion Pharmaceuticals plc (ISE:MERR), Dublin, Ireland Business: Drug delivery Hired: Hing Kin Chan as CBO, formerly CBO of DBV Technologies WIR Staff...
BioCentury | Feb 18, 2010
Cover Story

Gut punch to osteoporosis

...findings in that regard are promising and intriguing, said Thomas Leonard, VP and CSO of Merrion Pharmaceuticals plc...
...as dogs or monkeys-because murine models do not metabolize bone the same way humans do. Merrion...
...Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Merrion Pharmaceuticals plc...
Items per page:
1 - 10 of 45